Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Clinical Decision-Making for Alzheimer Disease Management
Experts provide their perspectives on clinical factors taken into consideration when deciding on a treatment plan for a patient with Alzheimer disease.
EP: 1.The Clinical and Economic Implications of Alzheimer Disease Across Patients, Families, and the Health Care System
EP: 2.Recent Insights into the Pathophysiology of Alzheimer Disease
EP: 3.Genetic Aspects of Alzheimer Disease
EP: 4.The Patient Experience: From Symptoms to Diagnosis of Alzheimer Disease
EP: 5.Potential Consequences of Early Diagnosis of Alzheimer Disease
EP: 6.Criteria for Diagnosing Alzheimer Disease and the Role of Testing
EP: 7.Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease
EP: 8.Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease
Now Viewing
EP: 9.Clinical Decision-Making for Alzheimer Disease Management
EP: 10.Cost, Value, and Affordability of Treatment for Alzheimer Disease
EP: 11.Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates
EP: 12.Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden
EP: 13.Payer Coverage Considerations for New Treatments for Alzheimer Disease
EP: 14.Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook
Video content above is prompted by the following question(s):
- When deciding on a treatment plan for a patient with AD, what clinical factors do you take into consideration? (eg, results of testing, time since diagnosis, severity of symptoms, impact on patient/family/caregivers, efficacy, mechanism of action, monitoring requirements)
Related Videos
Related Content
Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL
July 16th 2025Article
Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).
Read More
